Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
May warrant investigation of glycosaminoglycan modulation in calcific aortic valve disease; hypothesis-generating and requires prospective trials before clinical consideration.
Calcific aortic valve disease is frequently driven by ageing and the obesity-associated metabolic syndrome, and the increasing impact of these factors indicates that valve disease will become a cardiovascular disease of considerable significance. This disease is now thought to be an active cell-based disease process, which may therefore be amenable to therapeutic intervention. Some similarities are apparent with atherosclerosis. The accumulation of lipid, possibly by retention by proteoglycans and the attraction of inflammatory cells by hyaluronan, may be common to the early stages of both pathologies. The synthesis and structure of glycosaminoglycans, proteoglycans, and hyaluronan are exquisitely regulated, and the signalling pathways controlling these processes may provide tissue-specific opportunities for concomitant prevention of atherosclerosis and calcific aortic valve disease.
No takes yet. Share an insight, caveat, or question.
Grande‐Allen et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: